**KWF Kankerbestrijding**

Long-Term Programme Biomarkers 2025

**Checklist**

*The purpose of this checklist is to make a good assessment of whether you meet the criteria of the long-term programme. Before starting, carefully read the instructions below:*

1. *A checklist evaluated by KWF is required to participate in the programme.*
2. *You can* ***submit the checklist at anytime between the 3rd of September till 22nd of Oktober 2024, 12.00 CET as pdf file to*** [***biomarkers@kwf.nl***](mailto:biomarkers@kwf.nl)***.*** *We advise to submit the checklist as soon as possible, as this will leave more time to work on the pre-proposal.*
3. *The checklist will be evaluated within 2 weeks. If your project is in scope, you will receive an invitation to submit a pre-proposal in GMS (****deadline for pre-proposals****:* ***3 December 2024, 12.00 CET****). If your project is not in scope, you will receive a justification why it is not a fit and whether another KWF call might be a better choice (if applicable).*
4. *For any questions, please contact* [*biomarkers@kwf.nl*](mailto:biomarkers@kwf.nl)*.*

**Eligibility**

*Please tick the boxes if applicable:*

Biomarker development in/entering/higher than technology readiness level (TRL) 7.

Single intended context-of-use of the biomarker, i.e. either (early)detection or diagnosis or prognosis or patient selection.

Biomarker validation in independent cohort is completed.

Biomarker characteristics are determined (selectivity, sensitivity).

Multidisciplinary consortium experienced in development and commercialization (*if applicable*) and implementation of the biomarker.

**Project Details**

*Please provide the requested information:*

Project leader (name, department, institute):

Title of Project:

Intended run time (months):

**Brief summary**

|  |
| --- |
| *Please briefly summarize the proposal you would like to submit by addressing the following aspects: 1) Current situation and problem description, 2) Solution/intended approach, 3) Development steps, 4) Expected outcome and fit in current practice. Max. 200 words.*  Fill in text here…. |

**Status Biomarker**

|  |
| --- |
| *Briefly describe the current development status of the biomarker. You may want to include answers to the following questions in your explanation: Has the biomarker already been tested in a clinical setting/prospective study? Is the biomarker already in a format that can be implemented in clinical practice? Have you already taken steps towards commercialization and/or implementation of the biomarker? Max. 200 words.*  Fill in text here…. |

**References (optional)**

Fill in text here….